Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene

Merger appetites and competitive dynamics will continue to be assessed as investors grill the next round of biopharma companies presenting first quarter sales and earnings. Gilead and Pfizer will be particularly pressed on deals.